---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-010300"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-02-01T23:59:59+00:00"
generated_at: "2026-06-27T13:18:06.383531+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gilead settles Biktarvy patent litigation with ViiV for $1.25B upfront + 3% royalty through 2027

## Summary
- One-time payment of $1.25B to ViiV in Q1 2022; pre-tax charge of $1.25B recorded in Q4 2021.
- Ongoing 3% royalty on U.S. sales of Biktarvy and bictegravir products until October 5, 2027.
- Settlement resolves all pending and potential claims across U.S. and international jurisdictions.
- ViiV grants Gilead a broad worldwide license and covenant not to sue for bictegravir.

## SEC filing metadata
- accession: 0001104659-22-010300
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-02-01T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465922010300/0001104659-22-010300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465922010300/tm224824d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-010300
- JSON: https://secwatch.observer/filing/0001104659-22-010300.json
- Plain text: https://secwatch.observer/filing/0001104659-22-010300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.